This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)

Medical Information

IMAAVY - Dosage in Patients with Generalized Myasthenia Gravis

Last Updated: 04/29/2025

Summary

  • The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
  • Please refer to the local labeling for further information on dosage and administration of IMAAVY.

PRESCRIBING INFORMATION

DOSAGE AND ADMINISTRATION

Recommended Dosage1 

  • Dilute IMAAVY prior to administration. Administer via intravenous infusion only.
  • The recommended initial dosage of IMAAVY is 30 mg/kg administered once via intravenous infusion over at least 30 minutes.
  • Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dosage every two weeks thereafter.
  • If a scheduled infusion appointment is missed, the maintenance dosage of IMAAVY should be administered as soon as possible. Resume dosing every two weeks thereafter.

 

References

1 IMAAVY (nipocalimab-aahu) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc;https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/IMAAVY-pi.pdf